FDA Inspection 1102924 — Curie Manavata Cancer Centre

Curie Manavata Cancer Centre — FEI 3006429978

The FDA completed an inspection of Curie Manavata Cancer Centre on September 27, 2019 in Nashik. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 1 citation was issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
September 27, 2019
Fiscal Year
2019
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Nashik (India)

Additional Details

Clinical BA/BE

Citations

IDCFRDescription
756021 CFR 312.60FD-1572, protocol compliance